{"id":70759,"date":"2026-05-12T10:48:03","date_gmt":"2026-05-12T10:48:03","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70759"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"survodutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/survodutide\/","title":{"rendered":"Survodutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 Survodutide\uff08\u30b9\u30eb\u30dc\u30c7\u30e5\u30bf\u30a4\u30c9\uff09\u3068\u306f\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>Survodutide<\/strong> (developmental code BI 456906) is a 29-amino-acid long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. In published Phase 2 studies it produced striking effects in MASH (metabolic-dysfunction-associated steatohepatitis) liver fibrosis alongside obesity body-weight reductions of ~19% over 46 weeks. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2230198-02-2\uff08survodutide\uff1b\u4e00\u822c\u7684\u306b\u5f15\u7528\u3055\u308c\u308b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u30bf\u30a4\u30d7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9577\u6642\u9593\u4f5c\u7528\u578b\u306eGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u30c7\u30e5\u30a2\u30eb\u30b3\u30a2\u30b4\u30cb\u30b9\u30c8\uff08\u30a2\u30b7\u30eb\u5316\u5408\u6210\u30da\u30d7\u30c1\u30c9\uff1b\u30d9\u30fc\u30ea\u30f3\u30ac\u30fc\u30a4\u30f3\u30b2\u30eb\u30cf\u30a4\u30e0 BI 456906\uff1b\u30b8\u30fc\u30e9\u30f3\u30c9\u30d5\u30a1\u30fc\u30de\u3068\u5171\u540c\u958b\u767a\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~3,800 Da\uff08\u8102\u80aa\u9178\u30a2\u30b7\u30eb\u5316\u3092\u542b\u3080\uff1b\u6210\u719f\u30da\u30d7\u30c1\u30c9\u5f62\u614b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u69cb\u9020<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">DPP-4\u8010\u6027\u3092\u5f97\u308b\u305f\u3081\u306b\u4eba\u5de5\u7684\u306bAib\u7f6e\u63db\u304c\u5c0e\u5165\u3055\u308c\u3001\u03b3-Glu\u30ea\u30f3\u30ab\u30fc\u3092\u4ecb\u3057\u3066\u30ea\u30b7\u30f3\u6b8b\u57fa\u306b\u8102\u80aa\u9178\u4e8c\u9178\u30a2\u30b7\u30eb\u9396\u304c\u7d50\u5408\u3057\u305f29\u30a2\u30df\u30ce\u9178\u306e\u5408\u6210\u30da\u30d7\u30c1\u30c9\u30c7\u30e5\u30a2\u30eb\u30b3\u30a2\u30b4\u30cb\u30b9\u30c8\u3067\u3059\u3002\u30d0\u30e9\u30f3\u30b9\u306e\u53d6\u308c\u305f\u30c7\u30e5\u30a2\u30ebGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u6d3b\u6027\u3092\u7dad\u6301\u3057\u306a\u304c\u3089\u3001\u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u7531\u6765\u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\uff08\u30de\u30ba\u30c7\u30e5\u30bf\u30a4\u30c9 \u7d0439\u30a2\u30df\u30ce\u9178\uff09\u3088\u308a\u3082\u5927\u5e45\u306b\u77ed\u304f\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\uff08\u767d\u8272\u301c\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u4f7f\u7528\u6642\u5728\u5eab\u306f2\uff5e8\u2103\uff08\u51b7\u8535\uff09\u306b\u4fdd\u7ba1\u3002\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306b\u306f\u221220\u2103\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u2103\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u77ed\u671f\u9593\u4f7f\u7528\u306e\u5834\u5408\u306f\u6ec5\u83cc\u6c34\u3002\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u6eb6\u89e3\u306b\u6642\u9593\u304c\u304b\u304b\u308b\u5834\u5408\u304c\u3042\u308a\u307e\u3059 \u2014 \u5341\u5206\u306a\u5e73\u8861\u5316\u6642\u9593\u3092\u53d6\u3063\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Survodutide\u3068\u306f\uff1f<\/h2>\n<p><strong>Survodutide<\/strong> (developmental code BI 456906) is a long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It represents the Western pharmaceutical arm of the dual GLP-1\/glucagon co-agonist studies programme, alongside the parallel programmes that produced <a href=\"https:\/\/medsbase.com\/ja\/mazdutide\/\">mazdutide<\/a> (Innovent Biologics, China) and the older Pegapamodutide \/ Cotadutide compounds. Survodutide is structurally compact \u2014 just 29 amino acids \u2014 substantially shorter than the oxyntomodulin-derived dual agonists, while preserving balanced agonist activity at both target receptors through engineered substitutions and fatty-acid acylation. Survodutide has a mature molecular weight of approximately 3,800\u00a0Da including the acyl modification. The 29-residue length is one of the structural distinctives: shorter peptides are typically cheaper to synthesise per unit dose but have less surface area for fine-tuning receptor-balance pharmacology. Boehringer-Zealand achieved the dual-agonist balance through a combination of strategic Aib substitutions at DPP-4 cleavage sites and careful tuning of receptor-binding-pocket residues. Plasma half-life is approximately 6 days, supporting once-weekly subcutaneous dosing. The current clinical signature of survodutide is the <strong>\u9855\u8457\u306a MASH\uff08\u4ee3\u8b1d\u6a5f\u80fd\u969c\u5bb3\u95a2\u9023\u8102\u80aa\u6027\u809d\u708e\uff09\u809d\u7dda\u7dad\u75c7\u52b9\u679c<\/strong> \u7b2c2\u76f8\u8a66\u9a13\u3067\u5831\u544a\u3055\u308c\u307e\u3057\u305f \u2014 \u3053\u308c\u306f\u3001\u540c\u69d8\u306e\u4f53\u91cd\u6e1b\u5c11\u52b9\u679c\u3092\u6301\u3064\u4ed6\u306e\u4e8c\u91cd\u304a\u3088\u3073\u4e09\u91cd\u30a2\u30b4\u30cb\u30b9\u30c8\u3068\u306f\u7570\u306a\u308b\u7d50\u679c\u3067\u3059\u3002\u7b2c2\u76f8\u80a5\u6e80\u8a66\u9a13\u30c7\u30fc\u30bf\u3067\u306f\u30014.8 mg \u90311\u56de\u6295\u4e0e\u306746\u9031\u9593\u306b\u308f\u305f\u308a\u7d0419%\u306e\u4f53\u91cd\u6e1b\u5c11\u304c\u793a\u3055\u308c\u3001survodutide \u306f \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9 \u3068\u540c\u7b49\u306e\u52b9\u679c\u30b5\u30a4\u30ba\u306e\u968e\u5c64\u306b\u4f4d\u7f6e\u3057\u3001\u4e09\u91cd\u30a2\u30b4\u30cb\u30b9\u30c8 retatrutide \u306e\u5883\u754c\u306b\u9054\u3057\u3066\u3044\u307e\u3059\u3002Survodutide \u306f\u73fe\u5728\u3001\u80a5\u6e80\uff08SURMOUNT \u8a66\u9a13\u30c7\u30b6\u30a4\u30f3\u306b\u985e\u4f3c\uff09\u304a\u3088\u3073 MASH \u306e\u7b2c3\u76f8\u8a66\u9a13\u4e2d\u3067\u3059\u3002Survodutide \u306f <strong>\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the sibling dual GLP-1\/glucagon co-agonist, see our <a href=\"https:\/\/medsbase.com\/ja\/mazdutide\/\">Mazdutide<\/a> \u88fd\u54c1\u30da\u30fc\u30b8\uff1bGIP \u3092\u8ffd\u52a0\u3057\u305f\u4e09\u91cd\u4f5c\u52d5\u85ac\u306b\u3064\u3044\u3066\u306f\u3001 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a>. <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 \u809d\u81d3\u306b\u91cd\u70b9\u3092\u7f6e\u3044\u305f GLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u4e8c\u91cd\u5171\u4f5c\u52d5<\/h2>\n<p>\u30b9\u30eb\u30dc\u30c7\u30e5\u30bf\u30a4\u30c9\u304c\u4e8c\u91cd\u4f5c\u52d5\u85ac\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u306e\u4e2d\u3067\u30e1\u30ab\u30cb\u30ba\u30e0\u7684\u306b\u7279\u5fb4\u7684\u3067\u3042\u308b\u70b9\u306f <strong>\u6bd4\u8f03\u7684\u30d0\u30e9\u30f3\u30b9\u306e\u53d6\u308c\u305fGLP-1\u5bfe\u30b0\u30eb\u30ab\u30b4\u30f3\u306e\u52b9\u529b\u6bd4<\/strong> \u3053\u308c\u306f\u3001\u5927\u5e45\u306a\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u52b9\u679c\uff08\u30b0\u30eb\u30ab\u30b4\u30f3\u4f5c\u7528\uff09\u3068\u53e4\u5178\u7684\u306aGLP-1\u306e\u6e80\u8179\u611f\uff0f\u8840\u7cd6\u964d\u4e0b\u4f5c\u7528\u306e\u4e21\u65b9\u3092\u751f\u307f\u51fa\u3057\u3001\u7279\u306b\u809d\u81d3\u306e\u8ee2\u5e30\u306b\u91cd\u70b9\u3092\u7f6e\u3044\u3066\u3044\u307e\u3059\uff1a<\/p>\n<ul>\n<li><strong>GLP-1\u53d7\u5bb9\u4f53\u6d3b\u6027\u5316 \u2014 \u6e80\u8179\u611f\u3001\u03b2\u7d30\u80de\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u3001\u80c3\u6392\u51fa<\/strong> \u2014 \u30b9\u30eb\u30dc\u30c7\u30e5\u30bf\u30a4\u30c9\u306f\u3001\u81b5\u03b2\u7d30\u80de\uff08\u30b0\u30eb\u30b3\u30fc\u30b9\u4f9d\u5b58\u6027\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u3001\u03b1\u7d30\u80de\u304b\u3089\u306e\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\uff09\u3001\u8996\u5e8a\u4e0b\u90e8\u5f13\u72b6\u6838POMC\u30cb\u30e5\u30fc\u30ed\u30f3\uff08\u4e2d\u67a2\u6027\u98df\u6b32\u8abf\u7bc0\uff09\u3001\u80c3\u8ff7\u8d70\u795e\u7d4c\u6c42\u5fc3\u6027\u7dda\u7dad\uff08\u80c3\u5185\u5bb9\u7269\u6392\u51fa\u9045\u5ef6\uff09\u306eGLP-1\u53d7\u5bb9\u4f53\u3092\u6d3b\u6027\u5316\u3057\u307e\u3059\u3002\u3053\u306e\u4f5c\u7528\u306f\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u3084\u3001\u3059\u3079\u3066\u306e\u30de\u30eb\u30c1\u30a2\u30b4\u30cb\u30b9\u30c8\u30a4\u30f3\u30af\u30ec\u30c1\u30f3\u30da\u30d7\u30c1\u30c9\u306eGLP-1\u6210\u5206\u3068\u91cd\u8907\u3057\u3066\u3044\u307e\u3059\u3002<\/li>\n<li><strong>\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u6d3b\u6027\u5316 \u2014 \u809d\u81d3\u306e\u8102\u8cea\u52d5\u54e1\u3001\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u3001\u8910\u8272\u8102\u80aa\u7d44\u7e54\u306e\u6d3b\u6027\u5316<\/strong> \u2014 \u3068\u5171\u901a\u3059\u308b\u6c7a\u5b9a\u7684\u306a\u7279\u5fb4\u306f <a href=\"https:\/\/medsbase.com\/ja\/mazdutide\/\">mazdutide<\/a> KYC\uff08Know Your Customer\uff09 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9<\/a> is glucagon-receptor agonism. In survodutide studies, this arm produces particularly strong hepatic lipid mobilisation \u2014 hepatocytes are highly enriched for glucagon receptors, and direct glucagon-pathway activation drives fatty-acid oxidation and triglyceride export. The combined effect with the GLP-1 arm&#8217;s indirect liver benefits via reduced insulin resistance produces the distinctive MASH-fibrosis signal observed in Phase 2.<\/li>\n<li><strong>\u53d7\u5bb9\u4f53\u30d0\u30e9\u30f3\u30b9\u306e\u5de5\u5b66\u7684\u8a2d\u8a08\u3068\u4e8c\u91cd\u4f5c\u52d5\u85ac\u306e\u52b9\u529b\u6bd4<\/strong> \u2014 The pharmacological challenge in dual GLP-1\/glucagon co-agonism is achieving the right relative potency at each receptor. Glucagon agonism alone raises glucose; GLP-1 agonism alone produces strong glucose-lowering. The net effect depends on the in-vivo ratio of receptor occupancy at each site. Survodutide is engineered for a glucagon-favoured balance relative to mazdutide, which contributes to the stronger hepatic effects but requires more careful titration to avoid net glucose effects in early dose-escalation protocols.<\/li>\n<\/ul>\n<p>The fatty-acid acylation at a lysine residue (analogous in concept to semaglutide&#8217;s C18 acyl chain) drives reversible serum-albumin binding that produces the ~6-day plasma half-life and supports once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Survodutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>MASLD\/MASH\uff08\u4ee3\u8b1d\u6a5f\u80fd\u969c\u5bb3\u95a2\u9023\u809d\u75be\u60a3\uff09<\/strong> \u2014 hepatic triglyceride content, ALT\/AST normalisation, fibrosis-stage progression in preclinical models and clinical Phase 2 data; survodutide&#8217;s strongest signal and the basis for its dedicated MASH Phase 3 programme<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 \u524d\u81e8\u5e8aDIO\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u3001\u4f53\u7d44\u6210\uff08DEXA\/MRI\uff09\u3001\u98df\u7269\u6442\u53d6\u30a2\u30c3\u30bb\u30a4\u3001\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u6e2c\u5b9a<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 \u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u52d5\u614b\u3001HbA1c\u4ee3\u66ff\u30de\u30fc\u30ab\u30fc\uff1b\u8a2d\u8a08\u3055\u308c\u305f\u53d7\u5bb9\u4f53\u30d0\u30e9\u30f3\u30b9\u306f\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u6210\u5206\u306b\u3082\u304b\u304b\u308f\u3089\u305a\u6b63\u5473\u306e\u8840\u7cd6\u964d\u4e0b\u3092\u512a\u5148\u3057\u307e\u3059\u3002<\/li>\n<li><strong>Energy-expenditure and thermogenesis studies<\/strong> \u2014 \u5b89\u9759\u6642\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u3001\u8910\u8272\u8102\u80aa\u7d44\u7e54\u306e\u6d3b\u6027\u5316\u3001\u71b1\u7523\u751f\u907a\u4f1d\u5b50\u767a\u73fe\uff1b\u7279\u306b\u30b0\u30eb\u30ab\u30b4\u30f3\u4f5c\u7528\u306b\u95a2\u4fc2\u3059\u308b\u305f\u3081\u91cd\u8981\u3067\u3059<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 \u4ee3\u66ff\u306eGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u4e8c\u91cd\u4f5c\u52d5\u85ac\u3068\u306e\u76f4\u63a5\u6bd4\u8f03 <a href=\"https:\/\/medsbase.com\/ja\/mazdutide\/\">Mazdutide<\/a> \uff08\u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u7531\u6765\u300139\u30a2\u30df\u30ce\u9178\uff09\u3001GLP-1\/GIP\u4e8c\u91cd\u4f5c\u52d5\u85ac <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a>, \u3001\u304a\u3088\u3073\u4e09\u91cd\u4f5c\u52d5\u85ac <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a>; receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 \u8840\u5727\u3001\u8102\u8cea\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3078\u306e\u5f71\u97ff\uff1b\u7b2c2\u76f8\/\u7b2c3\u76f8\u8a66\u9a13\u304b\u3089\u84c4\u7a4d\u3055\u308c\u3064\u3064\u3042\u308b\u5fc3\u8840\u7ba1\u30a2\u30a6\u30c8\u30ab\u30e0\u30c7\u30fc\u30bf<\/li>\n<li><strong>\u30b0\u30eb\u30ab\u30b4\u30f3\u8ef8\u306e\u85ac\u7406\u5b66<\/strong> \u2014 \u5358\u96e2\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u85ac\u7406\u3001\u809d\u81d3\u306e\u30b0\u30eb\u30b3\u30fc\u30b9\u51fa\u529b\u52d5\u614b\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u5bfeGLP-1\u53d7\u5bb9\u4f53\u306e\u52b9\u529b\u30d0\u30e9\u30f3\u30b9\u306e\u7279\u6027\u89e3\u6790<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 GLP-1\u5358\u72ec\u4f5c\u52d5\u85ac\u3068\u306e\u6bd4\u8f03\uff08<a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a>) \u304a\u3088\u3073\u30a2\u30df\u30ea\u30f3\u8ef8\u4f75\u7528\u85ac\u7406\u5b66 (<a href=\"https:\/\/medsbase.com\/ja\/cagrilintide\/\">\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9<\/a> + \u30bb\u30de\u30b0\u30eb\u30c1\u30c9 CagriSema).<\/li>\n<\/ul>\n<p>survodutide\u304c\u30de\u30eb\u30c1\u30a2\u30b4\u30cb\u30b9\u30c8\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u306e\u5168\u4f53\u50cf\u306e\u4e2d\u3067\u3069\u306e\u3088\u3046\u306a\u4f4d\u7f6e\u3092\u5360\u3081\u308b\u304b\u306b\u3064\u3044\u3066\u306e\u3088\u308a\u5e83\u3044\u6587\u8108\u306b\u3064\u3044\u3066\u306f\u3001 <a href=\"https:\/\/medsbase.com\/ja\/mazdutide\/\">Mazdutide<\/a> GLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u5171\u4f5c\u52d5\u85ac\u306e\u5144\u5f1f\u85ac\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> GIP\u3092\u8ffd\u52a0\u3057\u305f\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a> \u30b0\u30eb\u30ab\u30b4\u30f3\u306e\u4ee3\u308f\u308a\u306bGIP\u3092\u7528\u3044\u305f\u4ee3\u66ff\u30c7\u30e5\u30a2\u30eb\u3068\u3057\u3066\u3001\u305d\u3057\u3066 <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> \u30b7\u30f3\u30b0\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u306e\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u3068\u3057\u3066\u3002\u5168\u30e9\u30a4\u30f3\u30ca\u30c3\u30d7\u3092\u898b\u308b <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks Survodutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u9577\u671f\u30b5\u30a4\u30af\u30eb\u30d7\u30ed\u30c8\u30b3\u30eb\u3001\u591a\u30b3\u30db\u30fc\u30c8\u7814\u7a76\u30011mg\u3042\u305f\u308a\u6700\u5b89\u30b3\u30b9\u30c8<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 2 clinical doses are 0.3\u20134.8\u00a0mg weekly with a 4\u20136 month titration schedule, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Survodutide is a comparatively scarce peptide because of active clinical development and Western-pharmaceutical supply-chain controls, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>\u6bd4\u8f03 \u2014 Survodutide\u5bfeMazdutide<\/h2>\n<p>Survodutide\u3068 <a href=\"https:\/\/medsbase.com\/ja\/mazdutide\/\">Mazdutide<\/a> are the two principal dual GLP-1 \/ glucagon co-agonist peptides in current literature. They share receptor pharmacology \u2014 both activate the GLP-1 and glucagon receptors, both lack GIP activity \u2014 but differ in structural origin, length, and engineered receptor-balance ratio. The comparison is one of the cleanest in current dual-agonist pharmacology because the receptor targets are identical and only the molecular implementation differs. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Survodutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53d7\u5bb9\u4f53\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon\uff08\u30c7\u30e5\u30a2\u30eb\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon\uff08\u30c7\u30e5\u30a2\u30eb\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a2\u30df\u30ce\u9178\u6570<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">29\u30a2\u30df\u30ce\u9178\uff08\u30b3\u30f3\u30d1\u30af\u30c8\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0439\u30a2\u30df\u30ce\u9178\uff08\u30aa\u30ad\u30b7\u30f3\u30c8\u30e2\u30b8\u30e5\u30ea\u30f3\u7531\u6765\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u958b\u767a\u4f01\u696d<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30d9\u30fc\u30ea\u30f3\u30ac\u30fc\u30a4\u30f3\u30b2\u30eb\u30cf\u30a4\u30e0 + Zealand Pharma<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent Biologics\uff08Eli Lilly\u304b\u3089\u30e9\u30a4\u30bb\u30f3\u30b9\u53d6\u5f97\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u958b\u767a\u30b3\u30fc\u30c9<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BI 456906<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">IBI362 \/ LY3305677<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53d7\u5bb9\u4f53\u30d0\u30e9\u30f3\u30b9<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30b0\u30eb\u30ab\u30b4\u30f3\u512a\u4f4d\uff08\u5f37\u529b\u306a\u809d\u81d3\u4f5c\u7528\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1\u512a\u4f4d\uff08\u3088\u308a\u30af\u30ea\u30fc\u30f3\u306a\u8840\u7cd6\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u534a\u6e1b\u671f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d046\u65e5\u9593\uff08\u90311\u56de\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u90311\u56de\uff08\u30a2\u30b7\u30eb\u5316\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u7279\u5fb4\u7684\u306a\u81e8\u5e8a\u30b7\u30b0\u30ca\u30eb<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">MASH\u809d\u7dda\u7dad\u75c7\u306e\u6539\u5584\uff08\u7b2c2\u76f8\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u521d\u306e\u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u627f\u8a8d\uff08\u4e2d\u56fdNMPA\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4f53\u91cd\u52b9\u679c<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0419%\uff08\u7b2c2\u76f8\u300146\u9031\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0415\uff5e17%\uff08\u7b2c3\u76f8\u300148\u9031\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0.3\u20134.8 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For MASH\/MASLD liver-disease studies, survodutide is the more frequently cited dual-agonist tool because of its distinctive Phase 2 hepatic-fibrosis signal. For studies interested in the glycaemic axis with minimal glucagon-pathway interference, mazdutide&#8217;s GLP-1-favoured balance is the cleaner choice. The two peptides together represent the principal Western (Boehringer-Zealand) and Eastern (Innovent) approaches to dual GLP-1\/glucagon co-agonist pharmacology \u2014 both are likely to remain in active studies and clinical development through this decade. <\/p>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u3001\u77ed\u671f\u4f7f\u7528\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u3001\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u307e\u3059\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u5b58\u306e\u5834\u5408\u306f\u3001-20\u00b0C\u3067\u51b7\u51cd\u3057\u307e\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u30b9\u30eb\u30dc\u30c7\u30e5\u30bf\u30a4\u30c9\u306f\u51b7\u8535\u3067\u6700\u957724\u304b\u6708\u3001-20\u00b0C\u3067\u6700\u957736\u304b\u6708\u5b89\u5b9a\u3067\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306e\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.9\u00a0mL delivers a 4.8\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>\u3057\u307e\u305b\u3093<\/strong> \u632f\u3068\u3046\u2014\u2014\u305d\u3057\u3066\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u9759\u7f6e\u3057\u307e\u3059\uff08\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u5c0f\u3055\u306a\u975e\u4fee\u98fe\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u6eb6\u89e3\u304c\u9045\u3044\uff09\u3002\u9069\u5207\u306b\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u3001\u6f84\u660e\u3067\u7121\u8272\u3001\u76ee\u306b\u898b\u3048\u308b\u7c92\u5b50\u304c\u306a\u3044\u306f\u305a\u3067\u3059\u3002 <strong>\u5b8c\u5168\u306b\u518d\u6eb6\u89e3\u3057\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3042\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/strong> \u6700\u9069\u306a\u5b89\u5b9a\u6027\u306e\u305f\u3081\u30012\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u69cb\u6210\u6eb6\u6db2\u3092\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044 \u2014 \u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u30da\u30d7\u30c1\u30c9\u306e\u5b8c\u5168\u6027\u3092\u52a3\u5316\u3055\u305b\u307e\u3059\u3002\u767d\u6fc1\u3001\u6c88\u6bbf\u3001\u307e\u305f\u306f\u5909\u8272\u304c\u898b\u3089\u308c\u308b\u30d0\u30a4\u30a2\u30eb\u306f\u5ec3\u68c4\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2 id=\"faqs\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>What is Survodutide used for in studies?<\/h3>\n<p>Survodutide is used in studies investigating MASLD\/MASH liver disease (its strongest distinctive signal), obesity and body-composition regulation, type 2 diabetes preclinical models, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), the sibling dual GLP-1\/glucagon mazdutide, and triple-agonist retatrutide. The pharmaceutical-grade survodutide sold here is <strong>\u3057\u307e\u305b\u3093<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u30b9\u30eb\u30dc\u30c7\u30e5\u30bf\u30a4\u30c9\u306f\u30de\u30ba\u30c7\u30e5\u30bf\u30a4\u30c9\u3068\u3069\u3046\u9055\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>Both are dual GLP-1\/glucagon co-agonists with the same receptor targets, but they differ in structural origin and engineered receptor-balance ratio. Survodutide is a compact 29-amino-acid Boehringer-Zealand compound with a glucagon-favoured potency balance that produces particularly strong hepatic effects (the basis for its Phase 2 MASH signal). Mazdutide is a ~39-amino-acid oxyntomodulin-derived Innovent compound with a GLP-1-favoured balance that produces cleaner glycaemic effects. For MASH studies, survodutide is the canonical choice; for clean glycaemic-axis studies with minimal glucagon interference, mazdutide is preferred. <\/p>\n<h3>\u30b9\u30eb\u30dc\u30c7\u30e5\u30bf\u30a4\u30c9\u306f\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3068\u3069\u3046\u9055\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u3069\u3061\u3089\u3082\u30c7\u30e5\u30a2\u30eb\u30a4\u30f3\u30af\u30ec\u30c1\u30f3\u4f5c\u52d5\u85ac\u3067\u3059\u304c\u3001\u7570\u306a\u308b\u7b2c\u4e8c\u53d7\u5bb9\u4f53\u3092\u6d3b\u6027\u5316\u3057\u307e\u3059\u3002\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306fGLP-1 + GIP\uff08SURMOUNT-1\u8a66\u9a13\u3067\u7d0422%\u306e\u4f53\u91cd\u6e1b\u5c11\u52b9\u679c\uff09\u3067\u3059\u3002Survodutide\u306fGLP-1 + \u30b0\u30eb\u30ab\u30b4\u30f3\uff08\u7b2c2\u76f8\u8a66\u9a13\u3067\u7d0419%\uff09\u3067\u3059\u3002\u3053\u306e2\u3064\u306e\u53d7\u5bb9\u4f53\u306e\u7d44\u307f\u5408\u308f\u305b\u306b\u3088\u308a\u3001\u8cea\u7684\u306b\u7570\u306a\u308b\u4ee3\u8b1d\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u304c\u751f\u3058\u307e\u3059\u3002GIP\u306f\u7a7a\u8179\u6642\u306e\u8102\u80aa\u7d30\u80de\u306e\u8102\u80aa\u5206\u89e3\u3092\u4fc3\u9032\u3057\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u306f\u5927\u5e45\u306a\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u3068\u809d\u81d3\u306e\u8102\u8cea\u52d5\u54e1\u3092\u8ffd\u52a0\u3057\u307e\u3059\u3002Survodutide\u306f\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u99c6\u52d5\u578b\u306e\u809d\u81d3\u8102\u8cea\u52b9\u679c\u306b\u3088\u308a\u3001\u72ec\u81ea\u306eMASH\u7dda\u7dad\u5316\u30b7\u30b0\u30ca\u30eb\u3092\u6301\u3063\u3066\u3044\u307e\u3059\u3002 <\/p>\n<h3>Survodutide\u306fRetatrutide\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>Retatrutide adds GIP receptor activation on top of GLP-1 + glucagon \u2014 it is a triple agonist. Survodutide stops at the dual combination. Retatrutide&#8217;s Phase 2 body-weight effect (~24%) is larger than survodutide&#8217;s (~19%), suggesting GIP adds substantial benefit. Survodutide has the stronger MASH signal in its respective Phase 2 trial. For studies isolating the dual GLP-1 + glucagon combination without the GIP confound, survodutide (and mazdutide) are the cleaner tools. <\/p>\n<h3>What is the typical Survodutide dose?<\/h3>\n<p>Published Phase 2 clinical protocols use weekly subcutaneous dosing with a long titration schedule starting at 0.3\u00a0mg and stepping through 0.9, 1.8, 2.4, 3.6 to a maintenance dose of 4.8\u00a0mg weekly over approximately 24 weeks. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.9\u00a0mL equals a 4.8\u00a0mg clinical-equivalent dose. <\/p>\n<h3>Survodutide\u306fFDA\u306b\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>No. Survodutide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 3 trials for obesity and MASH are ongoing as of current literature. <\/p>\n<h3>Survodutide\u306f\u3069\u306e\u3088\u3046\u306b\u4fdd\u7ba1\u3059\u3079\u304d\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f-20\u00b0C\u3067\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6eb6\u6db2\uff1a2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6eb6\u6db2\u306f\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306b\u3088\u308a\u30da\u30d7\u30c1\u30c9\u304c\u5206\u89e3\u3055\u308c\u307e\u3059\u3002\u5e38\u306b\u76f4\u5c04\u5149\u3092\u907f\u3051\u3066\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h3>Survodutide\u306f\u3069\u306e\u3088\u3046\u306b\u518d\u69cb\u6210\u3057\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u4e0a\u8a18\u306e\u6eb6\u89e3\u624b\u9806\u306b\u5f93\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u3092\u4f1d\u308f\u305b\u3066\u9759\u83cc\u6c34\u3092\u52a0\u3048\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\uff09\u3001\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3001\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u9759\u7f6e\u3057\u307e\u3059\uff08\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u5c0f\u3055\u306a\u672a\u4fee\u98fe\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u6eb6\u89e3\u306b\u6642\u9593\u304c\u304b\u304b\u308a\u307e\u3059\uff09\u3002\u3057 <strong>\u3057\u307e\u305b\u3093<\/strong> \u30d0\u30a4\u30a2\u30eb\u3092\u632f\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u518d\u6eb6\u89e3\u3055\u308c\u305f\u6eb6\u6db2\u306f\u900f\u660e\u3067\u7121\u8272\u3067\u3059\u30025 mg\u306e\u30d0\u30a4\u30a2\u30eb\u306b2.0 mL\u306e\u5e0c\u91c8\u6db2\u3092\u52a0\u3048\u305f\u5834\u5408\u3001\u4f5c\u696d\u6fc3\u5ea6\u306f2.5 mg\/mL\u3067\u3059\u3002 <\/p>\n<h3>MedsBase\u3067\u306f\u3069\u306e\u5bb9\u91cf\u306e\u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9\u3092\u53d6\u308a\u63c3\u3048\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>MedsBase carries Survodutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Why is Survodutide particularly relevant for MASH studies?<\/h3>\n<p>Survodutide&#8217;s glucagon-favoured dual-receptor balance produces especially strong hepatic effects in published studies. Hepatocytes are highly enriched for glucagon receptors, so glucagon-pathway activation directly drives fatty-acid oxidation and triglyceride export from steatotic liver. Combined with the GLP-1 arm&#8217;s indirect benefits via reduced insulin resistance, the dual effect on the liver translates into the striking MASH-fibrosis-stage improvement reported in the Phase 2 trial \u2014 an outcome that distinguished survodutide from other dual and triple agonists at comparable body-weight effects. <\/p>\n<h3>\u30b0\u30eb\u30ab\u30b4\u30f3\u6210\u5206\u306f\u9ad8\u8840\u7cd6\u3092\u5f15\u304d\u8d77\u3053\u3057\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u53e4\u5178\u7684\u306a\u300c\u30b0\u30eb\u30ab\u30b4\u30f3\u30d1\u30e9\u30c9\u30c3\u30af\u30b9\u300d\u306f\u3001\u4ed6\u306eGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u4e8c\u91cd\u4f5c\u7528\u85ac\u3068\u540c\u69d8\u306bSurvodutide\u306b\u3082\u5f53\u3066\u306f\u307e\u308a\u307e\u3059\u3002\u30b0\u30eb\u30ab\u30b4\u30f3\u5358\u72ec\u3067\u306f\u809d\u81d3\u306e\u7cd6\u65b0\u751f\u3092\u523a\u6fc0\u3057\u3066\u8840\u7cd6\u5024\u3092\u4e0a\u6607\u3055\u305b\u307e\u3059\u304c\u3001GLP-1\u6210\u5206\u304c\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u4fc3\u9032\u3068\u03b2\u7d30\u80de\u304a\u3088\u3073\u03b1\u7d30\u80de\u306b\u304a\u3051\u308b\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u3092\u901a\u3058\u3066\u512a\u4f4d\u306b\u8840\u7cd6\u964d\u4e0b\u4f5c\u7528\u3092\u767a\u63ee\u3057\u3001\u3053\u308c\u3092\u6253\u3061\u6d88\u3057\u307e\u3059\u3002Survodutide\u306e\u8a2d\u8a08\u3055\u308c\u305f\u53d7\u5bb9\u4f53\u30d0\u30e9\u30f3\u30b9\u6bd4\u306b\u3088\u308a\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u306e\u6d3b\u6027\u5316\u306b\u3082\u304b\u304b\u308f\u3089\u305a\u6b63\u5473\u306e\u8840\u7cd6\u964d\u4e0b\u304c\u9054\u6210\u3055\u308c\u307e\u3059\u3002\u516c\u8868\u3055\u308c\u305f\u7b2c2\u76f8\u8a66\u9a13\u30c7\u30fc\u30bf\u3067\u306f\u3001\u7dad\u6301\u7528\u91cf\u306b\u304a\u3044\u30662\u578b\u7cd6\u5c3f\u75c5\u30b3\u30db\u30fc\u30c8\u3067\u306e\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u6539\u5584\u304c\u78ba\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002 <\/p>\n<h3>Does Survodutide cause side reported effects?<\/h3>\n<p>\u6700\u3082\u4e00\u8cab\u3057\u305f\u6240\u898b\u306f\u6d88\u5316\u5668\u75c7\u72b6\u3067\u3042\u308a\u3001\u4ed6\u306eGLP-1\u7cfb\u30da\u30d7\u30c1\u30c9\u3068\u540c\u69d8\u306b\u3001\u5410\u304d\u6c17\u3001\u4e00\u904e\u6027\u306e\u98df\u6b32\u6291\u5236\u3001\u80c3\u6392\u51fa\u9045\u5ef6\u304c\u7528\u91cf\u4f9d\u5b58\u7684\u306b\u751f\u3058\u3001\u7b2c2\u76f8\u8a66\u9a13\u3067\u7528\u3044\u3089\u308c\u305f\u9577\u671f\u6f38\u5897\u30b9\u30b1\u30b8\u30e5\u30fc\u30eb\u306b\u3088\u308a\u8efd\u6e1b\u3059\u308b\u50be\u5411\u304c\u3042\u308a\u307e\u3059\u3002\u30b0\u30eb\u30ab\u30b4\u30f3\u6210\u5206\u306b\u95a2\u9023\u3059\u308b\u6240\u898b\u3068\u3057\u3066\u3001\u5b89\u9759\u6642\u5fc3\u62cd\u6570\u306e\u8efd\u5ea6\u4e0a\u6607\u3084\uff08\u307e\u308c\u306b\uff09\u4e00\u904e\u6027\u306e\u8840\u5727\u5909\u52d5\u304c\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u9577\u671f\u6f38\u5897\u30b9\u30b1\u30b8\u30e5\u30fc\u30eb\u306f\u3001\u3053\u308c\u3089\u306e\u5f71\u97ff\u3092\u6700\u5c0f\u9650\u306b\u6291\u3048\u308b\u305f\u3081\u306b\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u3002 <\/p>\n<h3>Survodutide\u306e\u534a\u6e1b\u671f\u306f\u3069\u306e\u304f\u3089\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>In preclinical and clinical studies, survodutide has a plasma half-life of approximately 6 days following subcutaneous administration, comparable to tirzepatide (~5 days) and slightly shorter than semaglutide (~7 days). The half-life is achieved by reversible binding to circulating serum albumin via the fatty-acid acyl tether at a lysine residue. <\/p>\n<h3>How long does Survodutide take to show effects in preclinical studies?<\/h3>\n<p>\u8010\u7cd6\u80fd\u304a\u3088\u3073\u80c3\u6392\u51fa\u306b\u5bfe\u3059\u308b\u6025\u6027\u306e\u85ac\u529b\u5b66\u7684\u52b9\u679c\u306f\u3001\u521d\u56de\u6295\u4e0e\u5f8c\u6570\u6642\u9593\u3067\u691c\u51fa\u53ef\u80fd\u3067\u3059\u3002DIO\uff08\u98df\u4e8b\u8a98\u767a\u6027\u80a5\u6e80\uff09\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u4f53\u91cd\u6e1b\u5c11\u52b9\u679c\u306f\u3001\u901a\u5e38\u3001\u90311\u56de\u6295\u4e0e\u306e1\uff5e2\u9031\u9593\u5f8c\u306b\u7d71\u8a08\u5b66\u7684\u306b\u6709\u610f\u306b\u306a\u308a\u307e\u3059\u3002MASLD\/MASH\u306b\u304a\u3051\u308b\u809d\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u542b\u6709\u91cf\u304a\u3088\u3073ALT\/AST\u6b63\u5e38\u5316\u3078\u306e\u52b9\u679c\u306f\u30018\uff5e16\u9031\u9593\u306e\u5b9a\u671f\u7684\u306a\u6295\u4e0e\u3092\u7d4c\u3066\u84c4\u7a4d\u3055\u308c\u307e\u3059\u3002\u6700\u5927\u306e\u4f53\u7d44\u6210\u52b9\u679c\u306f24\uff5e46\u9031\u9593\u304b\u3051\u3066\u73fe\u308c\u3001\u3053\u308c\u306f\u7b2c2\u76f8\u8a66\u9a13\u306e\u63a8\u79fb\u3068\u4e00\u81f4\u3057\u307e\u3059\u3002 <\/p>\n<h3>Survodutide\u3092\u5168\u4e16\u754c\u914d\u9001\u3067\u6ce8\u6587\u3067\u304d\u307e\u3059\u304b\uff1f<\/h3>\n<p>Yes. MedsBase ships Survodutide worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\">\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, MASH, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/mazdutide\/\"><strong>Mazdutide<\/strong><\/a> \u2014 \u5144\u5f1f\u95a2\u4fc2\u306b\u3042\u308bGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u4e8c\u91cd\u4f5c\u7528\u85ac \u2014 \u4ee3\u66ff\u53d7\u5bb9\u4f53\u30d0\u30e9\u30f3\u30b9\u6bd4<\/li>\n<li><a href=\"\/ja\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 GLP-1\/GIP\/\u30b0\u30eb\u30ab\u30b4\u30f3\u4e09\u91cd\u4f5c\u7528\u85ac \u2014 GLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u4e8c\u91cd\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306bGIP\u3092\u8ffd\u52a0<\/li>\n<li><a href=\"\/ja\/tirzepatide\/\"><strong>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/strong><\/a> \u2014 \u30c7\u30e5\u30a2\u30ebGLP-1\/GIP\u4f5c\u52d5\u85ac \u2014 \u30b0\u30eb\u30ab\u30b4\u30f3\u306e\u4ee3\u308f\u308a\u306bGIP\u3092\u7528\u3044\u305f\u4ee3\u66ff\u30c7\u30e5\u30a2\u30eb\u4f5c\u52d5\u85ac\u3067\u3059\u3002<\/li>\n<li><a href=\"\/ja\/semaglutide\/\"><strong>\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/strong><\/a> \u2014 \u5358\u4e00GLP-1\u4f5c\u52d5\u85ac \u2014 \u6a19\u6e96\u7684\u306a\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u6bd4\u8f03\u85ac\u3067\u3059\u3002<\/li>\n<li><a href=\"\/ja\/cagrilintide\/\"><strong>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9<\/strong><\/a> \u2014 \u30a2\u30df\u30ea\u30f3\u30a2\u30ca\u30ed\u30b0 \u2014 \u4ee3\u66ff\u306e\u4f75\u7528\u85ac\u7406\u5b66\u7684\u30a2\u30d7\u30ed\u30fc\u30c1\u3067\u3059\u3002<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>\u53c2\u8003\u6587\u732e<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 \u30c7\u30e5\u30a2\u30ebGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\u5171\u4f5c\u52d5\u85ac\u306e\u5168\u4f53\u50cf\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/strong><\/p>\n<p style=\"margin: 0;\">\u3059\u3079\u3066\u3092\u95b2\u89a7 <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\"><strong>\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/strong><\/a>, \u3001\u95a2\u9023\u3059\u308b\u30de\u30eb\u30c1\u4f5c\u52d5\u85ac\u5316\u5408\u7269\u3092\u542b\u307f\u3001 <a href=\"https:\/\/medsbase.com\/ja\/mazdutide\/\">Mazdutide<\/a> \uff08\u5144\u5f1f\u30c7\u30e5\u30a2\u30ebGLP-1\/\u30b0\u30eb\u30ab\u30b4\u30f3\uff09\u3001, <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> \uff08\u30c8\u30ea\u30d7\u30eb\u4f5c\u52d5\u85ac\uff09\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a> \uff08\u30c7\u30e5\u30a2\u30ebGLP-1\/GIP\uff09\u3002\u76f4\u63a5\u6bd4\u8f03\u30ac\u30a4\u30c9\uff1a <a href=\"https:\/\/medsbase.com\/ja\/retatrutide-vs-tirzepatide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9 vs \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9 \u2014 \u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8 vs \u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 GLP-1\uff0b\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u30c7\u30e5\u30a2\u30eb\u5171\u4f5c\u52d5\u85ac<br \/>\n\u2705 \u30b3\u30f3\u30d1\u30af\u30c8\u306a29\u30a2\u30df\u30ce\u9178\u306eBoehringer\/Zealand\u30da\u30d7\u30c1\u30c9\uff08BI 456906\uff09<br \/>\n\u2705 \u7b2c2\u76f8\u8a66\u9a13\u3067\u5f37\u529b\u306aMASH\u809d\u7dda\u7dad\u75c7\u6539\u5584\u30b7\u30b0\u30ca\u30eb<br \/>\n\u2705 \u30b0\u30eb\u30ab\u30b4\u30f3\u512a\u4f4d\u306e\u53d7\u5bb9\u4f53\u30d0\u30e9\u30f3\u30b9<br \/>\n\u2705 \u90311\u56de\u6295\u4e0e\uff08\u7d046\u65e5\u306e\u534a\u6e1b\u671f\uff09<\/p>\n<p><strong>Survodutide<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":70984,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,6286],"class_list":["post-70759","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-survodutide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/70759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=70759"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70984"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=70759"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=70759"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=70759"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=70759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}